Head & Neck/Thyroid Cancers
From the Journals
Blood test might detect multiple cancer types, study suggests
The test, which uses methylation patterns in plasma cell-free DNA, had specificity and sensitivity approaching those needed for population-based...
Commentary
Perspective from the heartland: Cancer care and research during a public health crisis
Dr. Alan P. Lyss examines how the COVID-19 pandemic has and will affect cancer care and research.
Latest News
Cancer care and COVID-19 in Seattle, the first U.S. epicenter
Feature
How is oncology adapting to COVID-19?
Feature
Disruptions in cancer care in the era of COVID-19
Conference Coverage
Largest meeting on cancer research canceled: AACR
Conference Coverage
Drug reduces oral mucositis without affecting tumor control
Locoregional control, distant metastasis, and survival rates were similar in patients who received the drug, GC4419, and those who did not.
Conference Coverage
RT plus checkpoint blockade active in head and neck cancer
At 2 years, the progression-free survival rate was 71%, and the overall survival rate was 75%.
Conference Coverage
For a time, an old drug helps with PFS in a head and neck cancer
Conference Coverage
10-year data show no benefit when adding cetuximab to radiation and cisplatin
There was no survival benefit when cetuximab was added to radiotherapy and cisplatin in patients with head and neck carcinoma.
Conference Coverage
‘Promising’ responses with preoperative immunotherapy in oral cavity cancer